NCT02617849

Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma

A Phase II Study of Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (actual)
• Sponsor: Wilson Miller · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multi-center, open-label, Phase II clinical trial evaluating pembrolizumab in combination with carboplatin/paclitaxel as a treatment in unresectable locally advanced or metastatic melanoma.

Conditions

• Metastatic Malignant Melanoma

Interventions

Type	Name	Description
DRUG	Pembrolizumab	200 mg IV every 3 weeks
DRUG	Carboplatin	AUC=6, every 3 weeks x 4
DRUG	Paclitaxel	175 mg/m2, every 3 weeks x 4

Timeline

• Start date: 2016-05-19
• Primary completion: 2021-12-01
• Completion: 2025-12-01
• First posted: 2015-12-01
• Last updated: 2021-02-18

Locations

2 sites across 1 country: Canada